多药耐药标志物ABCB1（MDR-1/P-糖蛋白）和ABCC1（MRP-1）在肾细胞癌中的表达。
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.
作者信息
Walsh Naomi, Larkin Annemarie, Kennedy Susan, Connolly Lisa, Ballot Jo, Ooi Wei, Gullo Giuseppe, Crown John, Clynes Martin, O'Driscoll Lorraine
机构信息
National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
出版信息
BMC Urol. 2009 Jun 24;9:6. doi: 10.1186/1471-2490-9-6.
BACKGROUND
Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease.
METHODS
In this retrospective study the expression of two of these transporter efflux pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in archival material from 95 renal cell carcinoma patients.
RESULTS
In the first study investigating MDR-1 P-gp and MRP-1 protein expression patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of tumours studied showing MDR-1 P-gp and MRP-1 positivity.
CONCLUSION
Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.
背景
肾细胞癌患者对传统化疗反应不佳，这种无反应性可能归因于多药耐药性（MDR）。肾癌中MDR的机制尚未完全了解，在各种癌症的化疗耐药性中起作用的ABC转运蛋白在该疾病中的具体作用尚未完全明确。
方法
在这项回顾性研究中，通过免疫组织化学对95例肾细胞癌患者存档材料中的两种转运蛋白外排泵，即MDR-1 P-糖蛋白（ABCB1）和MRP-1（ABCC1）的表达进行了研究。
结果
在第一项研究肾细胞癌患者中MDR-1 P-糖蛋白和MRP-1蛋白表达模式的研究中，观察到两种外排泵的高表达水平，所研究的肿瘤中有100%显示MDR-1 P-糖蛋白和MRP-1阳性。
结论
尽管这些发现并未证明其因果关系，但表达这些外排泵的肿瘤的高频率表明它们可能是这种肿瘤类型化疗耐药性的重要因素。
Zotero 插件